Navigation Links
Combo Therapy Shows Promise in Treating Brain Tumors
Date:1/18/2008

Radiation seeds, chemo wafers slowed disease, boosted survival

FRIDAY, Jan. 18 (HealthDay News) -- Implantation of radioactive seeds and chemotherapy wafers following surgery shows promise in treating malignant brain tumors, a new study finds.

The early-phase clinical trial, led by researchers at The Neuroscience Institute at the University of Cincinnati and University Hospital, included 34 patients who had the combination therapy after surgery to remove recurrent glioblastoma multiforme (GBM).

The study, designed to assess the safety and effectiveness of simultaneous use of radioactive seeds and chemotherapy wafers, found that median patient survival was 69 weeks. Almost 25 percent (eight) of the patients survived two years. Patients with recurrent GBM who receive conventional treatment (chemotherapy) have a median survival of about 26 weeks.

About 25 percent of patients developed brain tissue death, which was treated with surgery or hyperbaric oxygen and did not affect survival. That rate of brain tissue death appeared to be higher than what's seen in patients treated with either seeds or wafers alone.

"Treatment of recurrent GBM presents a major challenge to neurosurgeons and neuro-oncologists," study author Dr. Ronald Warnick, a professor of neurosurgery, said in a prepared statement.

"Glioblastoma is an aggressive, highly malignant tumor with unclear boundaries. Because of its diffuse nature, surgeons are unable to remove it completely, and it regrows in the majority of patients. Our aim is to find a way to keep the infiltrating glioblastoma cells from growing into adjacent, health tissue," he said.

The radiation seeds, each about the size of a grain of rice, deliver radiation to the targeted area for six months. The chemotherapy wafers, which are about the size of a nickel, are placed along the surface of the brain.

Compared with the use of either one alone, the combination of the seeds and wafers appeared to further delay disease progression and increase length of patient survival, Warnick said.

However, he noted that the effectiveness of the combination therapy is not definitive, because this study did not include a control group.

The study was published in the February issue of the Journal of Neurosurgery.

More information

The U.S. National Cancer Institute has more about brain tumors.



-- Robert Preidt



SOURCE: University of Cincinnati, news release, Jan. 18, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Combo Treatment Best for Elderly Lymphoma Patients
2. Combo Therapy Cuts Prostate Cancer Death Rates
3. Drug Combo Halves Death Risk for Severe COPD Patients
4. Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients
5. New Combo Treatment Extends Kidney Cancer Survival
6. Drug Combo With Antibiotic May Slow MS Progression
7. Combo PET/CT Scan Helps Spot Breast Cancers Spread
8. Drug Combos Effective Against Rheumatoid Arthritis
9. Drug Combo Boosts Multiple Myeloma Survival
10. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
11. Two-Drug Combo Fights Brain Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Combo Therapy Shows Promise in Treating Brain Tumors
(Date:3/27/2017)... ... March 27, 2017 , ... Biotechnology and ... and engagement over the household brands of Top-20 pharma by optimizing clinical trial ... partnering with the right outsourcing payments provider can provide the technology, infrastructure, and ...
(Date:3/27/2017)... ... March 27, 2017 , ... SyncDog, Inc. , the ... partners LG Business Solutions at ATARC Federal Mobile Computing Summit , March ... provide education and examination into the mobility tools and technology employed by the ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, the first ... for the Smart System® 20/20. CE Certification builds upon M&S's long-standing commitment to ... such as ANSI, ISO and proven test methods used in the field of ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... can quickly sideline athletes. A type of groin injury, it occurs when the ... to serious, intense pain in and around the lower torso, as well as ...
(Date:3/27/2017)... NY (PRWEB) , ... March 27, 2017 , ... ... in epigenetic research products enables researchers to pursue the recent RNA methylation “gold ... methylation . In light of the newfound characteristics of N6-methyladenosine, or m6A ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... ... that adult use in states where cannabis is legal will generate ... $559 million will be from cannabis specific taxes, such as ... remaining $96 million will be earned from state sales taxes that ...
(Date:3/27/2017)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... AGI-134, an immunotherapy for the treatment of multiple cancers, obtained ... featured at the upcoming American Association for Cancer Research ... to be held on April 1-5, 2017. ... An abstract titled ...
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
Breaking Medicine Technology: